Intranasal Glucagon and Energy Balance — INGEB  

Obesity Clinical Trial

Official title: Assessing the Effects of Intranasal Glucagon on Energy Balance in Humans

Status Recruiting

Clinical Trial Summary

People who are overweight often find it difficult to lose weight through diet and medications because weight loss reduces the amount of energy spent by the body and increases appetite. Glucagon, when given as an injection, reduces appetite and increases the amount of energy spent by the body, even when resting. Based on studies in animals, it does so by working on the brain. However, when gives as an injection it raises blood sugar levels by acting on the liver and therefore it is not used as a weight loss drug. It has previously been shown that hormones such as glucagon, when given as a spray through the nose, can reach the brain with no major effect on the liver. Importantly it does not increase blood sugar. In this study the research team is investigating whether nasal glucagon reduces appetite and increases energy spent by the body compared to a placebo spray. If it does, it may be a potential treatment for losing weight.

Clinical Trial Description

Resting energy expenditure, appetite and food intake is being investigated in up to 20 individuals. Participants are their own control in a single-blind, placebo-controlled, crossover design. Participants are admitted after an overnight fast and allowed to rest for 1 hour before either intranasal glucagon (0.7mg) or intranasal placebo (sterile diluent) is administered. Study visits occur 1-3 weeks apart with intranasal glucagon or placebo applied in random order. Resting energy expenditure is measured via indirect calorimetry at baseline and over 90 minutes post-spray in 10-20 minute segments. Blood samples are taken at baseline and at regular intervals post-spray to measure glucagon, glucose and other hormones/metabolites. Appetite is assessed by visual analogue scale at 90 minutes post-spray followed by provision of a buffet-style meal for ad libitum food intake measurement. ;

Related Conditions & MeSH terms

• Obesity

• NCT number: NCT03650582
• Study type: Interventional
• Source: University Health Network, Toronto
• Contact: Priska Stahel, PhD
• Phone: 416-581-7487
• Email: priska.stahel@uhn.ca
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: June 6, 2017
• Completion date: October 30, 2018